Anatomy of an Epidemic

Robert Whitaker opens with a puzzle. Over the past 50 years, American society has embraced the belief that psychiatry made revolutionary advances, beginning with the antipsychotic Thorazine in 1954 and accelerating with newer drugs like Prozac in the late 1980s. If these drugs represent genuine progress, disability rates should have declined; instead, they skyrocketed. In 1955, one in every 468 Americans was hospitalized for mental illness; by 2007, one in every 76 received federal disability payments for a psychiatric condition. The number of children receiving Supplemental Security Income (SSI) for mental illness rose 35-fold between 1987 and 2007. Whitaker poses the central question: Could the drug-based paradigm of care itself be fueling this epidemic?

Before examining the scientific literature, Whitaker presents case studies illustrating divergent outcomes. George Badillo, diagnosed with paranoid schizophrenia, endured nine years of hospitalizations on antipsychotics before secretly stopping his medication, at which point his recovery began. Monica Briggs became manic within weeks of starting an antidepressant, was diagnosed with bipolar disorder, and spent 20 years cycling through hospitals before improving dramatically when she stopped antidepressants and remained on lithium, a mood-stabilizing drug, alone. Dorea Vierling-Claassen, diagnosed as bipolar after developing agitation on an antidepressant, weaned herself from all medications and thrived as a researcher and mother.

Whitaker traces the roots of the psychopharmacology revolution—psychiatry's systematic use of drugs to treat mental illness—to the "magic bullet" model of medicine pioneered by German scientist Paul Ehrlich, who demonstrated in 1909 that chemicals could selectively target disease-causing microbes. Breakthroughs including sulfa drugs, penicillin, and insulin fueled public faith in medicine's power to conquer disease. After World War II, Congress created the National Institute of Mental Health (NIMH) in 1949, setting the stage for psychiatry to find its own magic bullets.

The first psychiatric drugs, however, were discovered by accident. Thorazine originated from research on surgical anesthetics; when French psychiatrists administered it to psychotic patients in 1952, they described a drug that induced emotional indifference, a state they compared to encephalitis lethargica, a brain-damaging viral illness. The first anti-anxiety drug came from antibiotic research, and the first antidepressant was derived from rocket fuel and repurposed as a tuberculosis medication. Despite these origins, the drugs were rebranded as disease-specific treatments through media hype and pharmaceutical marketing.

This rebranding gained scientific cover in the mid-1960s when researchers proposed the chemical imbalance theory. Neurotransmitters are chemical messengers that brain cells use to communicate, and the new hypotheses proposed that depression resulted from deficient serotonin while schizophrenia resulted from excessive dopamine. Both arose from backward logic: researchers observed what the drugs did to neurotransmitters and theorized the opposite condition must cause the disease. Over the following decades, studies consistently failed to confirm either theory. Former NIMH director Steve Hyman wrote that there was "no compelling evidence that a lesion in the dopamine system is a primary cause of schizophrenia" (77). Rather than correcting imbalances, Whitaker argues, the drugs create them. Prozac blocks serotonin reuptake—the process by which neurons reabsorb the neurotransmitter after releasing it—triggering compensatory changes that, as Hyman wrote in a 1996 paper, leave the brain functioning in a manner "qualitatively as well as quantitatively different from the normal state" (83).

The core of the book examines decades of outcomes research across four diagnostic categories. For schizophrenia, before Thorazine, 62 to 73 percent of first-episode psychotic patients were discharged from hospitals within one to three years. Three NIMH-funded studies in the 1970s found unmedicated patients had better long-term outcomes. Researchers at McGill University explained the mechanism: The drugs increase dopamine receptor density in the brain, making patients more vulnerable to psychosis. Psychiatrist Martin Harrow's 15-year NIMH-funded study found that 40 percent of patients who stopped antipsychotics recovered, versus only 5 percent of those who remained on them.

For benzodiazepines, anti-anxiety drugs such as Valium and Xanax, the pattern is similar. These drugs amplify the effects of GABA, a brain chemical that dampens neural activity, but the brain compensates by reducing its own GABA output. Withdrawal produces rebound anxiety worse than the original condition. Karl Rickels at the University of Pennsylvania found that patients who quit benzodiazepines became "more alert, more relaxed, and less anxious" than those who stayed on them (137).

For depression, Whitaker establishes that in the pre-drug era, most episodes resolved within months, and 50 to 70 percent of patients experienced only a single episode. Researcher Irving Kirsch's 2008 analysis found antidepressant efficacy only marginally exceeded placebo. Italian psychiatrist Giovanni Fava argued that antidepressants may "propel the illness to a more malignant and treatment unresponsive course" (160) by sensitizing patients to depression. Observational studies outside controlled trials supported this: Dutch investigators found 76 percent of unmedicated patients recovered and never relapsed over 10 years, versus 50 percent of medicated patients.

For bipolar disorder, Whitaker traces how a rare, episodic illness became common and chronic. In 1955, about 12,750 people were hospitalized with it; half never had a second attack, and 85 percent returned to work. The epidemic has been fueled by iatrogenic pathways, meaning illness caused by medical treatment, particularly antidepressant-induced mania. Yale researchers found antidepressant users converted to bipolar at three times the rate of unexposed patients. The NIMH's STEP-BD study found antidepressant use was "the major predictor of worse outcome" (187). In Harrow's study, bipolar patients off medications recovered to near-normal functioning, while those on medications fared worse than unmedicated schizophrenia patients.

Whitaker extends this analysis to children. The rise of attention-deficit/hyperactivity disorder (ADHD) was driven by expanded diagnostic boundaries, and stimulants like Ritalin made children more compliant but did not improve academic achievement. The NIMH's major long-term study found that by year three, medication use was "a significant marker not of beneficial outcome, but of deterioration" (227). The juvenile bipolar epidemic followed from stimulant and antidepressant prescribing: a Food and Drug Administration (FDA) review found nearly 1,000 reports of stimulant-induced mania in children between 2000 and 2005, representing an estimated 100,000 actual cases. These children were then placed on drug cocktails including atypical antipsychotics, a newer class of drugs, locking them into chronic illness.

Whitaker synthesizes these findings to argue that the epidemic is largely caused by the drugs prescribed to treat it. People with serious mental illness now die 15 to 25 years earlier than the general population, driven by cardiovascular disease and metabolic dysfunction associated with long-term drug use.

The book's penultimate section traces how the false narrative of psychiatric progress was constructed. In the late 1970s, the American Psychiatric Association (APA) responded to declining drug sales and professional competition by redefining psychiatric disorders as biological diseases in its 1980 Diagnostic and Statistical Manual (DSM-III) and forging a financial partnership with the pharmaceutical industry. Drug companies provided funding, academic psychiatrists conferred legitimacy, the NIMH provided government endorsement, and the National Alliance on Mental Illness (NAMI), a parent advocacy group receiving millions in pharmaceutical funding, provided moral authority. Pharmaceutical companies distorted trial data: Germany's licensing authority initially rejected Prozac as "totally unsuitable for the treatment of depression" (286), but Eli Lilly manipulated trial protocols and reclassified adverse events. Academic psychiatrists published more than 20 articles claiming newer drugs' superiority despite FDA warnings against such claims. By 2008, U.S. psychotropic drug sales exceeded $40 billion.

The book closes with alternative approaches. In western Lapland, Finland, open-dialogue therapy treats first-episode psychotic patients with family-based meetings while delaying antipsychotic use; five-year outcomes show 79 percent of patients asymptomatic, 80 percent working or in school, and new schizophrenia cases down 90 percent. Whitaker concludes that reform requires breaking the partnership between psychiatry and the pharmaceutical industry and conducting an honest public discussion about what outcomes research actually shows.